Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FT596
- Development stage
- Discontinued
- Lead developer
- Fate Therapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies, iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
FT596 is an investigational, universal, off-the-shelf natural killer (NK) cell cancer immunotherapy derived from a clonal master induced pluripotent stem cell (iPSC) line. It is engineered with three active anti-tumor components: a chimeric antigen receptor (CAR) targeting CD19; a high-affinity non-cleavable CD16 Fc receptor to enhance antibody-dependent cellular cytotoxicity and enable combination with monoclonal antibodies such as rituximab (targeting CD20); and an IL-15/IL-15 receptor fusion to promote NK cell survival and proliferation without systemic cytokine support. This multi-antigen targeting approach aims to overcome resistance due to antigen escape in B-cell malignancies. FT596 is designed for scalable, standardized manufacturing and off-the-shelf use in patients with relapsed or refractory B-cell lymphoma and leukemia[1][3][5][6][8].
- Other names
- iPSC-derived CD16/IL-15RF-expressing anti-CD19 CAR-NK cells
02
Targets
CD19 (B lymphocyte antigen CD19)IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)IgG1 Fc (Immunoglobulin G1 Fc region)
Beyond the preview
Go deeper on FT596.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FT596.